公开(公告)号：EP2195451A1

公开(公告)日：2010-06-16

申请号：EP08795537.3

申请日：2008-08-22

申请人： Merck Sharp & Dohme Corp. ,  Rosetta Inpharmatics LLC ,  Dana-Farber Cancer Institute, Inc.

发明人： BERGSTROM, Donald ,  DAI, Xudong ,  HARDWICK, James ,  LIBERATOR, Cole ,  LOOK, A. Thomas ,  O'NEIL, Jennifer ,  RAO, Sudhir ,  STRACK, Peter ,  WINTER, Christopher ,  ZHANG, Theresa

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106

摘要： The invention relates to the identification and use of gene expression profiles with clinical relevance to the treatment of cellular proliferative disorders, especially those mediated by aberrant Notch signaling using a Notch signaling inhibitor. In particular, the invention provides the identities of genes, whose individual or cumulative expression patterns may be useful in various assays. The gene expression profiles, whether embodied in nucleic acid expression, protein expression, or other expression formats, may be used to select subjects afflicted with a Notch mediated cancer who will likely respond to treatment with a gamma-secretase inhibitor or another Notch inhibiting agent. The same markers may be used in the classification of patients being treated with other Notch inhibitors. The methods may further comprise providing diagnostic, prognostic, or predictive information based on the classifying step. The methods may further comprise selecting a treatment based on the classifying step.

公开(公告)号：EP3110509B1

公开(公告)日：2020-08-19

申请号：EP15754598.9

申请日：2015-02-23

申请人： Merck Sharp & Dohme Corp.

发明人： STRACK, Peter ,  BOOHER, Robert

IPC分类号： A61K31/519 ,  A61K31/496 ,  A61K45/06 ,  A61P35/02

公开(公告)号：EP3110509A1

公开(公告)日：2017-01-04

申请号：EP15754598.9

申请日：2015-02-23

申请人： Merck Sharp & Dohme Corp.

发明人： STRACK, Peter ,  BOOHER, Robert

IPC分类号： A61P35/02

摘要： A method for the treatment of cancer by administering a therapeutically effective amount of a cyclin-dependent kinase inhibitor with a therapeutically effective amount of a B cell chronic lymphocytic leukemia/lymphoma 2 inhibitor.

摘要翻译： 通过给予治疗有效量的细胞周期蛋白依赖性激酶（CDK）抑制剂和治疗有效量的B细胞慢性淋巴细胞白血病/淋巴瘤2抑制剂（“B细胞CLL /淋巴瘤2”或 “BCL-2”）。 CDK抑制剂和BCL-2抑制剂的施用可以是同时的，连续的或分开的。